$69.6
+0.42
(+0.61%)▲
0.86%
Downside
Day's Volatility :1.64%
Upside
0.78%
3.55%
Downside
52 Weeks Volatility :29.24%
Upside
26.64%
Period | Edwards Lifesciences Corp. | |
---|---|---|
3 Months | -24.39% | |
6 Months | -16.85% | |
1 Year | -19.05% | |
3 Years | -13.69% |
Market Capitalization | 42.1B |
Book Value | $10.49 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 2.24 |
PE Ratio | 30.88 |
PEG Ratio | 3.07 |
Wall Street Target Price | 96.74 |
Profit Margin | 24.56% |
Operating Margin TTM | 28.44% |
Return On Assets TTM | 11.54% |
Return On Equity TTM | 22.4% |
Revenue TTM | 5.7B |
Revenue Per Share TTM | 9.25 |
Quarterly Revenue Growth YOY | 11.4% |
Gross Profit TTM | 4.3B |
EBITDA | 1.8B |
Diluted Eps TTM | 2.24 |
Quarterly Earnings Growth YOY | -0.23 |
EPS Estimate Current Year | 2.55 |
EPS Estimate Next Year | 2.88 |
EPS Estimate Current Quarter | 0.65 |
EPS Estimate Next Quarter | 0.63 |
What analysts predicted
Upside of 38.99%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 3.4B | ↑ 15.91% |
Net Income | 583.6M | ↑ 2.48% |
Net Profit Margin | 16.99% | ↓ 2.23% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | ↑ 8.37% |
Net Income | 722.2M | ↑ 23.75% |
Net Profit Margin | 19.4% | ↑ 2.41% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.3B | ↑ 16.79% |
Net Income | 1.0B | ↑ 44.96% |
Net Profit Margin | 24.08% | ↑ 4.68% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 4.4B | ↑ 0.88% |
Net Income | 823.4M | ↓ 21.35% |
Net Profit Margin | 18.77% | ↓ 5.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 5.2B | ↑ 19.29% |
Net Income | 1.5B | ↑ 82.55% |
Net Profit Margin | 28.73% | ↑ 9.96% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 5.4B | ↑ 2.86% |
Net Income | 1.5B | ↑ 1.25% |
Net Profit Margin | 28.28% | ↓ 0.45% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.3B | ↑ 0.86% |
Net Income | 373.6M | ↑ 11.42% |
Net Profit Margin | 27.86% | ↑ 2.64% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.4B | ↑ 2.44% |
Net Income | 406.4M | ↑ 8.78% |
Net Profit Margin | 29.58% | ↑ 1.72% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.3B | ↓ 4.0% |
Net Income | 343.5M | ↓ 15.48% |
Net Profit Margin | 26.04% | ↓ 3.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.3B | ↑ 2.22% |
Net Income | 398.4M | ↑ 15.98% |
Net Profit Margin | 29.55% | ↑ 3.51% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↑ 8.25% |
Net Income | 340.5M | ↓ 14.53% |
Net Profit Margin | 23.33% | ↓ 6.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↑ 4.84% |
Net Income | 305.5M | ↓ 10.28% |
Net Profit Margin | 19.96% | ↓ 3.37% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 5.7B | ↑ 26.29% |
Total Liabilities | 2.7B | ↑ 44.88% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 5.3B | ↓ 6.53% |
Total Liabilities | 2.2B | ↓ 20.31% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 6.5B | ↑ 21.87% |
Total Liabilities | 2.3B | ↑ 7.17% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 7.2B | ↑ 11.54% |
Total Liabilities | 2.7B | ↑ 13.8% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 8.5B | ↑ 17.49% |
Total Liabilities | 2.7B | ↑ 0.15% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 8.3B | ↓ 2.47% |
Total Liabilities | 2.5B | ↓ 6.78% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 8.4B | ↓ 0.97% |
Total Liabilities | 2.6B | ↓ 3.44% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 8.4B | ↑ 0.06% |
Total Liabilities | 2.5B | ↓ 3.63% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 8.6B | ↑ 2.53% |
Total Liabilities | 2.4B | ↓ 2.46% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 8.3B | ↓ 4.0% |
Total Liabilities | 2.5B | ↑ 2.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.7B | ↑ 4.33% |
Total Liabilities | 2.6B | ↑ 4.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.0B | ↑ 4.08% |
Total Liabilities | 2.6B | ↓ 1.22% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.0B | ↑ 42.06% |
Investing Cash Flow | -647.2M | ↑ 205.72% |
Financing Cash Flow | -473.2M | ↑ 76.24% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 926.8M | ↓ 7.38% |
Investing Cash Flow | 76.7M | ↓ 111.85% |
Financing Cash Flow | -1.1B | ↑ 132.71% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↑ 27.26% |
Investing Cash Flow | -595.8M | ↓ 876.79% |
Financing Cash Flow | -115.6M | ↓ 89.5% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↓ 10.61% |
Investing Cash Flow | -531.1M | ↓ 10.86% |
Financing Cash Flow | -486.9M | ↑ 321.19% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↑ 64.29% |
Investing Cash Flow | -1.7B | ↑ 224.33% |
Financing Cash Flow | -356.3M | ↓ 26.82% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 293.3M | ↓ 21.49% |
Investing Cash Flow | 229.5M | ↓ 123.76% |
Financing Cash Flow | -368.1M | ↑ 493.71% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 332.2M | ↑ 13.26% |
Investing Cash Flow | 129.6M | ↓ 43.53% |
Financing Cash Flow | -308.1M | ↓ 16.3% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 309.9M | ↓ 6.71% |
Investing Cash Flow | -201.5M | ↓ 255.48% |
Financing Cash Flow | -69.9M | ↓ 77.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 314.1M | ↑ 11.07% |
Investing Cash Flow | 500.0K | - |
Financing Cash Flow | -206.6M | ↓ 75.36% |
Sell
Neutral
Buy
Edwards Lifesciences Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Edwards Lifesciences Corp. | -8.94% | -16.85% | -19.05% | -13.69% | 33.26% |
![]() Stryker Corporation | -7.13% | -7.39% | 26.9% | 27.93% | 57.77% |
![]() Boston Scientific Corp. | -3.3% | 2.94% | 28.71% | 34.58% | 38.97% |
![]() Abbott Laboratories | -5.11% | -6.88% | -7.13% | -11.82% | 33.29% |
![]() Medtronic Plc | -3.03% | -2.14% | -7.96% | -25.01% | -19.81% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Edwards Lifesciences Corp. | 30.93 | 30.93 | 3.07 | 2.55 | 0.22 | 0.12 | 0.0 | 10.49 |
![]() Stryker Corporation | 38.68 | 38.68 | 2.85 | 10.36 | 0.16 | 0.06 | 0.01 | 45.71 |
![]() Boston Scientific Corp. | 89.49 | 89.49 | 2.53 | 2.0 | 0.05 | 0.04 | 0.0 | 12.46 |
![]() Abbott Laboratories | 33.05 | 33.05 | 18.76 | 4.39 | 0.14 | 0.06 | 0.02 | 21.42 |
![]() Medtronic Plc | 28.92 | 28.92 | 3.04 | 5.28 | 0.07 | 0.04 | 0.04 | 38.47 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Edwards Lifesciences Corp. | Buy | $42.1B | 33.26% | 30.93 | 24.56% |
![]() Stryker Corporation | Buy | $104.0B | 57.77% | 38.68 | 13.92% |
![]() Boston Scientific Corp. | Buy | $77.3B | 38.97% | 89.49 | 6.81% |
![]() Abbott Laboratories | Buy | $168.1B | 33.29% | 33.05 | 12.83% |
![]() Medtronic Plc | Buy | $104.3B | -19.81% | 28.92 | 11.47% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Capital Research & Mgmt Co - Division 3
AllianceBernstein L.P.
Bank of New York Mellon Corp
edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
Organization | Edwards Lifesciences Corp. |
Employees | 17300 |
CEO | Mr. Michael A. Mussallem |
Industry | Health Technology |